<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336381">
  <stage>Registered</stage>
  <submitdate>8/01/2011</submitdate>
  <approvaldate>15/02/2011</approvaldate>
  <actrnumber>ACTRN12611000175976</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of artesunate and dihydroartemisinin-piperaquine tablets for the treatment of uncomplicated Plasmodium falciparum malaria  and  Chloroquine for the treatment of Plasmodium  vivax malaria in Bu Dang of Binh Phuoc, Tuy Duc of Dak Nong, Huong Hoa of Quang Tri and Gia Lai provinces, Viet Nam in 2010</studytitle>
    <scientifictitle>Efficacy and safety of artesunate and dihydroartemisinin-piperaquine tablets for the treatment of uncomplicated Plasmodium falciparum malaria  and  Chloroquine for the treatment of Plasmodium  vivax malaria in Bu Dang of Binh Phuoc, Tuy Duc of Dak Nong, Huong Hoa of Quang Tri and Gia Lai provinces, Viet Nam in 2010</scientifictitle>
    <utrn>U1111-1118-8979</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The efficacy and safety of 3 drugs used by the control program as anti-malarial standard treatment, artesunate, DHA-PIP and CQ, will be assessed separately in 4 different groups of patients in 3 different study sites. Pf malaria patients in Binh Phuoc and Dak Nong sites will receive Artesunate for 7 days; Pf patienst in Quang Tri and Gia Lai will recieve co-formulated DHA-PIP for 3 days; and vivax patienst in Quang Tri will receive CQ. 
- Oral artesunate (50 mg/tab) will be administered at a total dose of 16 mg/kgbw over 7 days (1st day: 4 mg/kgbw, 2nd to 7th days: 2 mg/kgbw/day). 
- Oral dihydroartemisinin-piperaquine(DHA-PIP) will be administered at a dose of 2mg/kg/day DHA and 16mg/kg/day PIP for 3 days.
- Oral chloroquine will be administered at a total dose of 25mg/kgbw (10 mg/kgbw on day0, 10mg/kgbw on day1 and 5 mg/kgbw on day2).
The WHO 28 day in vivo protocol, used in this study, consists of parasite count and temperature measurements at baseline (day0 before dosing) and on days 1, 2, 3, 7, 14, 21 and 28.</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Outcome 1: 28/42 -day cure rate or ACPR (adequate clinical and parasitological response)
 (absence of parasitaemia on day 28/42, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure)</outcome>
      <timepoint>after start of the study : Day 1, Day 2, Day 3, Day 7, Day 14, Day 21, Day 28, Day 35 and Day 42</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PCR-corrected ACPR  (PCR: polymerase chain reaction, a molecular tool/test to differentiate if the failure is a true resistance or reinfection)</outcome>
      <timepoint>after start of study (Day 7, Day 14, Day 21, Day 28 with artesunate, chloroquine, Day 35 and Day 42 with Dihydroartemisinin - Piperaquine)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- age between 02  to  60 years old; 
- mono-infection with P. falciparum  or P. vivax detected by microscopy;
- Pf= parasitaemia of  500  100,000 asexual forms/ micro ml of blood;
- Pv = parasitemia 250-50,000 asexual forms/ micro ml of blood;
- presence of axillary  temperature greater than or equal 
 37.5 degrees Centigrade or history of fever during the past 24 h;
- ability to swallow oral medication;
- ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
- informed consent from the patient or from a parent or guardian in the case of children.</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
- mixed or mono-infection with another Plasmodium species detected by microscopy;
- presence of severe malnutrition (defined as a child whose growth standard is below 3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference &lt; 110 mm);
- presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- regular medication, which may interfere with antimalarial pharmacokinetics;
- history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); and
- Single female with  ages  12  18 years  old. 
- a positive pregnancy test or breastfeeding.
- unable to or unwilling to take contraceptives (for women of child-bearing age).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Viet Nam</country>
      <state>Binh Phuoc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Viet Nam</country>
      <state>Dak Nong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Viet Nam</country>
      <state>Quang Tri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Viet Nam</country>
      <state>Gia Lai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministry of Health</primarysponsorname>
    <primarysponsoraddress>138A  Giang Vo street, Ba Dinh, Ha Noi, 10.000</primarysponsoraddress>
    <primarysponsorcountry>Viet Nam</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>World Health Organization</fundingname>
      <fundingaddress>World Health Organization Western Pacific Regional Office, United Nations Avenue, Manila 1000</fundingaddress>
      <fundingcountry>Philippines</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Global Funds</fundingname>
      <fundingaddress>Ministry of Health
138A  Giang Vo street, Ba Dinh, Ha Noi 10.000</fundingaddress>
      <fundingcountry>Viet Nam</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>IMPE Ho Chi Minh</sponsorname>
      <sponsoraddress>699 Tran Hung Dao street, ward 5, Ho Chi Minh City, 70.000</sponsoraddress>
      <sponsorcountry>Viet Nam</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>IMPE Qui  Nhon</sponsorname>
      <sponsoraddress>611B, Nguyen Thai Hoc street, Qui Nhon city, Binh Dinh province, 53.000</sponsoraddress>
      <sponsorcountry>Viet Nam</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Binh Phuoc  malaria control center</othercollaboratorname>
      <othercollaboratoraddress>14 road, Tien Thanh Commune, Dong Xoai Town, Binh Phuoc Province, 77.000</othercollaboratoraddress>
      <othercollaboratorcountry>Viet Nam</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Dak Nong Provincial Malaria Center</othercollaboratorname>
      <othercollaboratoraddress>Nghia Tan Commune, Gia Nghia town, Dak Nong Province</othercollaboratoraddress>
      <othercollaboratorcountry>Viet Nam</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This surveillance study is a one-arm prospective evaluation of the clinical and parasitological responses to directly observed treatment for uncomplicated malaria. The objective is to assess the efficacy and safety of dihydroartemisinin-piperaquine (DHA-PIP) and artesunate (AS7) monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine (CQ) for the treatment of Plasmodium vivax malaria in 4 sites in Vietnam.  The drugs and study sites are: AS7 in Bu Dang of Binh Phuoc and Tuy Duc of Dak Nong, DHA-PIP in Gia Lai, and DHA-PIP and CQ in Huong Hoa of Quang Tri, Viet Nam.  The WHO 28-day in vivo protocol will be used.  People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, treated on site with the ACT DHA-PIP or 7-day artesunate or chloroquine.</summary>
    <trialwebsite>WWW.nimpe.com.vn</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of National Institute of malariology, Parasitology and Entomology</ethicname>
      <ethicaddress>245 Luong The Vinh Street, Trung Van, Tu Liem, Hanoi
10.200</ethicaddress>
      <ethicapprovaldate>10/04/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>29/03/2010</ethicsubmitdate>
      <ethiccountry>Viet Nam</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>WHO WPRO Ethics Review Committee (ERC)</ethicname>
      <ethicaddress>WHO Western Pacific Regional Office, United NAtionas Avenue, Manila 1000</ethicaddress>
      <ethicapprovaldate>19/07/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>30/04/2010</ethicsubmitdate>
      <ethiccountry>Philippines</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ta Thi Tinh</name>
      <address>Head of Malaria Research &amp; Treatment Department.
Natinal Institute of Malariology, Parasitology and Entomology
245 Luong The Vinh street, Trung van, Tu Liem, Ha Noi
10.200</address>
      <phone>+84912684889</phone>
      <fax>+84 438543015</fax>
      <email>tinhnimpe@yahoo.com</email>
      <country>Viet Nam</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tran Cong Dai</name>
      <address>WHO Vietnam
 63 Tran  Hung Dao Street, Ha Noi, 10.000</address>
      <phone>+84 9132011706</phone>
      <fax />
      <email>TranCongD@wpro.who.int</email>
      <country>Viet Nam</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ta Thi Tinh</name>
      <address>Head of Malaria Research &amp; Treatment Department.
Natinal Institute of Malariology, Parasitology and Entomology
245 Luong The Vinh street, Trung van, Tu Liem, Ha Noi
10.200</address>
      <phone>+84912684889</phone>
      <fax>+84 438543015</fax>
      <email>tinhnimpe@yahoo.com</email>
      <country>Viet Nam</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>